[Fosun Pharma: Its controlled subsidiary drug FXS5626 has been approved for clinical trials] On September 8, Fosun Pharmaceutical (600196.SH) announced that the company's controlled subsidiary Fosun Pharmaceutical Industries has received approval from the National Medical Products Administration to conduct a Phase II/III adaptive seamless design clinical trial of FXS5626 tablets for the treatment of non-segmental vitiligo. The drug is an oral small molecule JAK inhibitor, and the company enjoys the exclusive rights to research, develop, produce, register and commercialize it in China, Hong Kong and Macao. As of the announcement date, the cumulative R&D investment in this drug was approximately 108 million yuan, and no similar TYK2/JAK1 dual-target inhibitor has been approved for marketing in China.